HeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease. Using continuous wavelet transform (CWT) signal processing, MyoVista® Wavelet ECG (wavECG) advances cardiac screening capabilities by measuring myocardial energy to identify repolarization abnormalities associated with LVDD, even in asymptomatic patients. The MyoVista wavECG Device bridges the “diagnostic gap” in cardiac care by providing new low-cost testing to provide physicians with new information to assist in risk-assessment for heart disease and in determining whether a patient should receive further testing, evaluation and or treatment.
MyoVista Wavelet ECG (wavECG) - Breakthrough Technology for Low-Cost Early Detection of Cardiac Dysfunction in the Diastolic Phase
ACC.19 Learning Pathways? (select one) Heart Failure and Cardiomyopathies